Gevorg Tamamyan։ We Are Looking for Champions Around the World

Phase 3 BATTMAN Trial Launches BOT/BAL in MSS or pMMR Metastatic Colorectal Cancer

OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition

immunosarc II Trial: Sunitinib + Nivolumab in Advanced Clear Cell Sarcoma

2 New ES-SCLC Treatments Backed by EMA: A Major Shift in Care

Pavankumar Anné: Excited to be joining OncoDaily for the upcoming ZS AI in Oncology session during ASCO

Waleed Arafat: Final Days to Submit Abstracts for ISCO 2026

Dr. Richard Goldberg on Why FDA Must Keep Pace as CRC Rises in Younger Adults

Calculators

Body Mass Index (BMI)

Cockcroft-Gault Creatinine Clearance Calculator

BSA Calculator – Body Surface Area

Carboplatin Dose Calculator (Calvert Formula)

Child-Pugh Score Calculator

ECOG Score Calculator

IBW / Adjusted Body Weight (Devine Formula)

Bone Scan Index (BSI) Tracker

Khorana Score (Cancer-Associated VTE Risk)

MASCC Risk Index Calculator (Febrile Neutropenia)

IMDC Risk Score Calculator (Metastatic RCC)

Oncotype DX Recurrence Score (RS) Categorizer

Cisplatin Cumulative Dose Toxicity Tracker

CTCAE v6.0 Adverse Events Grader

Grade adverse events based on CTCAE v6.0 criteria. Select an adverse event and enter the lab value or clinical finding to determine the severity grade (1-5).

Enter the lab value or clinical finding

CTCAE v6.0 Grade Scale:

  • Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
  • Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting instrumental ADL.
  • Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated.
  • Grade 4: Life-threatening consequences; urgent intervention indicated.
  • Grade 5: Death related to AE.